Oppenheimer Reports On AMSG 2Q

Oppenheimer has issued a report following the AmSurg Corporation AMSG 2Q results. According to the report, "AmSurg reported 2Q11 EPS of $0.41, in line with our estimate and consensus. This includes $0.02 in transaction costs related to the pending acquisition of National Surgical Care (NSC). Excluding these costs, the company generated EPS of $0.43, exceeding its guidance of $0.40-0.42." AMSG is rated Underperform and closed yesterday at $26.39 a share.